A Phase i Dose Escalation Study to Determine the Optimal Biological Dose of Irosustat, an Oral Steroid Sulfatase Inhibitor, in Postmenopausal Women with Estrogen Receptor-Positive Breast Cancer
AuthID
P-008-BZR
P-008-BZR